Clinical trial
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00074971 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00074971 |
|---|---|
| Title | A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease |
| Official title | A Multi-center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Fabrazyme (agalsidase beta) |
| Enrollment | 58 |
| Start date | Oct 1, 1999 |
| Completion | Dec 1, 2004 |
| First posted | Dec 25, 2003 |
| Last update posted | Dec 4, 2013 |
| Countries | France, Netherlands, Puerto Rico, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: